Smart sharps disposal study for hemophilia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new, safer way to dispose of used needles and syringes (called SharpsCue) for people with hemophilia who give themselves regular infusions of factor or emicizumab. The goal is to see if the device makes disposal easier and safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have moderate or severe hemophilia A or B (with or without an inhibitor).
- You must be taking a factor product or emicizumab at least once every 14 days to prevent bleeds.
- You must not have a home nurse giving you infusions.
- You must be able to use the SharpsCue container.
- You cannot be in another study or take another investigational drug during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KN057 for people with severe hemophilia A or moderate-to-severe hemophilia B, whether or not they have developed inhibitors (antibodies that block standard treatments). The goal is to see if it can help prevent or treat bleeding episodes.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This trial studies Hemlibra (emicizumab) in people with mild congenital hemophilia A to see how well it works and what safety issues may occur. It may help reduce bleeding in patients who meet the study’s specific health and safety requirements.
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Hemophilia A and B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.